Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
about
Guidelines for the management of chronic kidney diseaseSpironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.Can you trust your animal study data?Renin-angiotensin system blockade is effective in reducing proteinuria of patients with progressive nephropathy caused by MYH9 mutations (Fechtner-Epstein syndrome).Sources of Urinary Proteins and their Analysis by Urinary Proteomics for the Detection of Biomarkers of DiseaseTunable detection sensitivity of opiates in urine via a label-free porous silicon competitive inhibition immunosensor.Assessment of proteinuria in patients with chronic kidney disease stage 3: albuminuria and non-albumin proteinuria.Early change in proteinuria as a surrogate end point for kidney disease progression: an individual patient meta-analysisNovel therapies for resistant focal segmental glomerulosclerosis (FONT) phase II clinical trial: study designRisk factors for CKD progression in Japanese patients: findings from the Chronic Kidney Disease Japan Cohort (CKD-JAC) study.Optimal proteinuria target for renoprotection in patients with IgA nephropathy.Effects of Benazepril on Survival of Dogs with Chronic Kidney Disease: A Multicenter, Randomized, Blinded, Placebo-Controlled Clinical Trial.Kidney and recipient weight incompatibility reduces long-term graft survivalLaboratory test surveillance following acute kidney injuryModerate antiproteinuric effect of add-on aldosterone blockade with eplerenone in non-diabetic chronic kidney disease. A randomized cross-over study.Analysis of correlation between 24-hour urinary sodium and the degree of blood pressure control in patients with chronic kidney disease and non-chronic kidney disease.Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes.Non-immunologic actions of calcineurin inhibitors in proteinuric kidney diseases.Reduction in basal nitric oxide activity causes albuminuriaAsymptomatic microscopic or dipstick haematuria in adults: which investigations for which patients? A review of the evidence.Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trialEarly change in proteinuria as a surrogate outcome in kidney disease progression: a systematic review of previous analyses and creation of a patient-level pooled dataset.Between-patient differences in the renal response to renin-angiotensin system intervention: clue to optimising renoprotective therapy?Role of angiotensin converting enzyme inhibitors and angiotensin receptor blockers in hypertension of chronic kidney disease and renoprotection. Study resultsThe evolution of treatment guidelines for diabetic nephropathy. Strategies integrate JNC VI, more recent protocols.Dipstick proteinuria as a screening strategy to identify rapid renal decline.Progression of pediatric CKD of nonglomerular origin in the CKiD cohort.Inhibition of RAS in diabetic nephropathy.Urinary sodium is a potent correlate of proteinuria: lessons from the chronic renal insufficiency cohort studyMicroalbuminuria in type 2 diabetics: an important, overlooked cardiovascular risk factor.Angiotensin II receptor blockers: the importance of dose in cardiovascular and renal risk reduction.FK506 reduces albuminuria through improving podocyte nephrin and podocin expression in diabetic rats.Microalbuminuria: definition, detection, and clinical significance.Diabetic nephropathy: the proteinuria hypothesis.Competing risk of death and end-stage renal disease in incident chronic kidney disease (stages 3 to 5): the EPIRAN community-based studySignificance of clinical and morphological prognostic risk factors in IgA nephropathy: follow-up study of comparison patient groups with and without renoprotectionProviding end-organ protection with renin-angiotensin system inhibition: the evidence so far.Losartan: lessons learned from the RENAAL study.Dipstick proteinuria as a predictor of all-cause and cardiovascular disease mortality in Bangladesh: A prospective cohort study.High burden and unmet patient needs in chronic kidney disease.
P2860
Q24657844-5A721F63-2E51-4186-BA41-2891FA0136A9Q30585060-B2412511-5C89-4A9C-B5C8-C71DEB9BD00AQ30829341-4D5D5A5E-3C13-4DB4-ADB1-6A11BBFC14E1Q33379734-B186A1C6-1C5B-437B-82CC-0AC2B75D706BQ33597457-3FB50F5A-3EAD-48EB-868B-0115C0CB4ADAQ33622530-92C05FFC-6EBA-4D6D-818E-42488154B107Q33670462-6E637CB8-40FF-40FA-B694-8EAC68287448Q33805412-2C3D9DF3-2660-4428-9A8B-E0ECFE49871EQ33817568-1B2B7B9F-51F6-413D-9C51-A57E215ACB42Q33840325-B5BD7879-A3C8-4139-8313-97A736CD540CQ33864287-12CBCB26-1B2C-4F69-8B23-E5756CD02A16Q33900224-36428D2A-1B3A-4872-93E3-FE779C483953Q33979306-4C543CFA-17ED-40C8-980E-75E9E441DDAAQ34035017-1C953310-8458-4783-9FDD-797630C59529Q34071671-D63575F8-1B1F-426B-8398-6FCA4326FABCQ34325366-AF81745D-CB32-4C9E-8B11-E3B1A1781FB3Q34331403-EBAF68C7-E357-451B-910A-7BFB63B474F9Q34496366-22CF3093-613A-4479-914C-494ED0C018EEQ34527146-E9D42A59-3655-4FA4-841E-022685B2F7F4Q34754190-52CD2942-C0AB-403E-8AD2-78B0E9688E96Q34891823-DB5FF8B3-CF30-45F0-8025-87F58B876E33Q35025425-FA62740D-F7C4-40A5-8172-E14C823A7568Q35065516-2DAF853B-8C51-4C49-9A73-5D2632117775Q35115546-2C7EBE98-88E8-4646-9862-611A38BC1116Q35135132-20189214-4622-44AE-87C5-EE3F5D0868A7Q35210221-3CC49A53-3C8A-457C-A6E5-2A67F5FBAE39Q35278515-C060890E-FE5F-4EDF-8869-88B43A77F64DQ35491275-C668400D-6537-4C9B-8BCA-F3DCACC2E01AQ35664862-263A4B7F-F83B-4B0D-A15E-D6469CE87101Q35686501-7CE4644E-D5D6-45AC-8231-79E004995BCBQ35799000-69978F8C-579B-4660-953E-EC0A3B032990Q35841085-B60D9138-E9C2-42E4-9ACC-1EFE204156CCQ35945733-7DFF6D60-B652-484A-9789-EF2DC232D134Q36061335-B4116A46-58DA-4E4F-B190-E26FB3B532B6Q36193259-D55A56CF-9767-48B6-AE53-BDF7CF1E51D9Q36307746-36E0AED7-4F38-4415-B48F-E52A3D14EFACQ36392674-A6FFC118-9352-4B16-A370-42D1E3A1B9E6Q36428522-8067BD03-78B4-49F1-8F59-CB57B6D3689DQ36479003-D25787C9-31C1-4B9D-BBF7-3C3B09CCBB63Q36500612-CF5A6569-F656-45C1-939C-3646BE6B2B7D
P2860
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease.
description
2001 nî lūn-bûn
@nan
2001年の論文
@ja
2001年学术文章
@wuu
2001年学术文章
@zh-cn
2001年学术文章
@zh-hans
2001年学术文章
@zh-my
2001年学术文章
@zh-sg
2001年學術文章
@yue
2001年學術文章
@zh
2001年學術文章
@zh-hant
name
Proteinuria as a modifiable ri ...... of non-diabetic renal disease.
@en
Proteinuria as a modifiable ri ...... of non-diabetic renal disease.
@nl
type
label
Proteinuria as a modifiable ri ...... of non-diabetic renal disease.
@en
Proteinuria as a modifiable ri ...... of non-diabetic renal disease.
@nl
prefLabel
Proteinuria as a modifiable ri ...... of non-diabetic renal disease.
@en
Proteinuria as a modifiable ri ...... of non-diabetic renal disease.
@nl
P2093
P50
P1433
P1476
Proteinuria as a modifiable risk factor for the progression of non-diabetic renal disease
@en
P2093
AIPRD Study Group. Angiotensin ...... d Progression of Renal Disease
C Marcantoni
D de Zeeuw
P E de Jong
S Shahinfar
P304
P356
10.1046/J.1523-1755.2001.0600031131.X
P407
P577
2001-09-01T00:00:00Z
P5875
P6179
1029857673